Related Experiment Video
Updated: Jun 19, 2026
09:37
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Are polymorphisms in the ACE and PAI-1 genes associated with recurrent spontaneous miscarriages?
Chelsi Goodman1, Jee Hur, Cyle S Goodman
1CARI Reproductive Institute, Chicago, IL, USA.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)
|October 14, 2009
Summary
Genetic analysis revealed that neither the ACE D/D genotype nor the combined ACE D/D and PAI-1 4G/4G genotypes significantly increase the risk of recurrent pregnancy loss.
Area of Science:
- Reproductive genetics
- Human molecular genetics
Background:
- Recurrent pregnancy loss (RPL) affects a significant number of women.
- Genetic factors are implicated in RPL, prompting investigation into specific gene polymorphisms.
Purpose of the Study:
- To investigate the association between the Angiotensin-Converting Enzyme (ACE) D/D genotype and the Plasminogen Activator Inhibitor-1 (PAI-1) 4G/4G genotype with recurrent pregnancy loss.
Main Methods:
- DNA was extracted from buccal swabs of 120 women with RPL and 84 controls.
- Multiplex PCR was used to analyze ACE gene insertion/deletion (I/D) polymorphism and PAI-1 4G/4G genotype.
Main Results:
- No significant difference in ACE gene mutations was found between RPL patients and controls.
- The prevalence of combined ACE D/D and PAI-1 4G/4G genotypes did not differ significantly between groups.
Conclusions:
- Homozygosity for the ACE D allele is not a significant risk factor for recurrent miscarriage.
- The combination of ACE D/D and PAI-1 4G/4G genotypes is not associated with an increased risk of recurrent pregnancy loss.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
02:30Genomic Imprinting and Inheritance
Diploid organisms inherit genetic material through chromosomes from both parents. Copies of the same gene are known as alleles. In most cases, both alleles are simultaneously expressed and allow various cellular processes to function optimally. If one of the alleles is missing or mutated, the expression of the other allele can compensate; however, this is not true for all genes.
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
02:57piRNA - Piwi-interacting RNAs
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
02:41Lethal Alleles
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...